153 related articles for article (PubMed ID: 38195387)
41. [Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature].
Adam Z; Szturz P; Krejčí M; Koukalová R; Michalková E; Řehák Z; Pourová E; Pour L; Volfová P; Sandecká V; Čermáková Z; Křen L; Sokol F; Hanke I; Penka I; Petrášová H; Ševčíková S; Král Z; Mayer J
Vnitr Lek; 2016 Apr; 62(4):287-98. PubMed ID: 27250606
[TBL] [Abstract][Full Text] [Related]
42. Treatment of Idiopathic Castleman Disease.
van Rhee F; Greenway A; Stone K
Hematol Oncol Clin North Am; 2018 Feb; 32(1):89-106. PubMed ID: 29157622
[TBL] [Abstract][Full Text] [Related]
43. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease.
Zhang L; Zhao AL; Duan MH; Li ZY; Cao XX; Feng J; Zhou DB; Zhong DR; Fajgenbaum DC; Li J
Blood; 2019 Apr; 133(16):1720-1728. PubMed ID: 30760451
[TBL] [Abstract][Full Text] [Related]
44. Dose selection of siltuximab for multicentric Castleman's disease.
Mayer CL; Xie L; Bandekar R; Qi M; van de Velde H; Reddy M; Qin X; Davis HM; Puchalski TA
Cancer Chemother Pharmacol; 2015 May; 75(5):1037-45. PubMed ID: 25784388
[TBL] [Abstract][Full Text] [Related]
45. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy.
Mukherjee S; Martin R; Sande B; Paige JS; Fajgenbaum DC
Blood Adv; 2022 Jan; 6(2):359-367. PubMed ID: 34535010
[TBL] [Abstract][Full Text] [Related]
46. Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.
Tonialini L; Bonfichi M; Ferrero S; Malipiero G; Nozza A; Argnani L; Zinzani PL
Hematol Oncol; 2018 Oct; 36(4):689-692. PubMed ID: 30074630
[TBL] [Abstract][Full Text] [Related]
47. POEMS Syndrome: Presented as Idiopathic Multicentric Castleman Disease of Plasma Cell Variant for Eight Years and Dramatic Treatment with Siltuximab Followed by Autologous Peripheral Blood Stem Cell Transplantation.
Lee YM; Choi YS; Kim JM
Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35454046
[TBL] [Abstract][Full Text] [Related]
48. Idiopathic multicentric Castleman disease with Sjögren's syndrome and secondary membranous nephropathy: a case report and review of the literature.
Pan Y; Cui Z; Wang S; Zheng D; Deng Z; Tian X; Guo H; Bao W; Zhou S; Wang Y
BMC Nephrol; 2020 Dec; 21(1):528. PubMed ID: 33276741
[TBL] [Abstract][Full Text] [Related]
49. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M; Wong R; Wu D; Maillard I; Brandstadter J; Munshi N; Bowne W; Elenitoba-Johnson KS; Fössa A; Lechowicz MJ; Chandrakasan S; Pierson SK; Greenway A; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Chadburn A; Fajgenbaum DC
Blood Adv; 2020 Dec; 4(23):6039-6050. PubMed ID: 33284946
[TBL] [Abstract][Full Text] [Related]
50. Frontline Siltuximab and Rituximab in TAFRO syndrome: A case report.
Marchetti M; Feyles E; Zinzani P
Eur J Haematol; 2020 Oct; 105(4):505-507. PubMed ID: 32564425
[No Abstract] [Full Text] [Related]
51. The role of interleukin 6 in the pathogenesis and therapy of Castleman disease - an immunologist's perspective.
Milota T; Střížová Z; Sobotková M; Bartůňková J
Cas Lek Cesk; 2023; 162(2-3):106-111. PubMed ID: 37474295
[TBL] [Abstract][Full Text] [Related]
52. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
Nishimoto N; Sasai M; Shima Y; Nakagawa M; Matsumoto T; Shirai T; Kishimoto T; Yoshizaki K
Blood; 2000 Jan; 95(1):56-61. PubMed ID: 10607684
[TBL] [Abstract][Full Text] [Related]
53. Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances.
Lang E; van Rhee F
Blood Rev; 2024 Mar; 64():101161. PubMed ID: 38087716
[TBL] [Abstract][Full Text] [Related]
54. Population pharmacokinetics of siltuximab: impact of disease state.
Nikanjam M; Yang J; Capparelli EV
Cancer Chemother Pharmacol; 2019 Nov; 84(5):993-1001. PubMed ID: 31482226
[TBL] [Abstract][Full Text] [Related]
55. Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology.
Soudet S; Fajgenbaum D; Delattre C; Forestier A; Hachulla E; Hatron PY; Launay D; Terriou L
Curr Res Transl Med; 2018 Sep; 66(3):83-86. PubMed ID: 30108026
[TBL] [Abstract][Full Text] [Related]
56. Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra).
El-Osta H; Janku F; Kurzrock R
Mol Cancer Ther; 2010 Jun; 9(6):1485-8. PubMed ID: 20501803
[TBL] [Abstract][Full Text] [Related]
57. Cutaneous castleman's disease responds to anti interleukin-6 treatment.
Ahmed B; Tschen JA; Cohen PR; Zaki MH; Rady PL; Tyring SK; Corringham RE; Kurzrock R
Mol Cancer Ther; 2007 Sep; 6(9):2386-90. PubMed ID: 17766835
[TBL] [Abstract][Full Text] [Related]
58. Siltuximab (Sylvant). Castleman's disease: good symptomatic efficacy in some patients.
Prescrire Int; 2016 Mar; 25(169):61-4. PubMed ID: 27152394
[TBL] [Abstract][Full Text] [Related]
59. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
[TBL] [Abstract][Full Text] [Related]
60. The Role of Interleukin-6 in Castleman Disease.
Yoshizaki K; Murayama S; Ito H; Koga T
Hematol Oncol Clin North Am; 2018 Feb; 32(1):23-36. PubMed ID: 29157617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
